引用本文:[点击复制]
[点击复制]
【打印本页】 【在线阅读全文】【下载PDF全文】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 59次   下载 22 本文二维码信息
码上扫一扫!
慢性心力衰竭患者住院期间β受体阻滞剂的使用情况
曾静,王小波,卢圣忠,梁豪,秦丹,胡厚祥
0
(川北医学院附属医院心内科)
摘要:
【摘要】 目的 了解我院心内科慢性心力衰竭患者住院期间β受体阻滞剂使用情况。方法 采用川北医学院附属医院住院患者病例数据库选取2017年心内科的慢性心力衰竭患者,并对其β受体阻滞剂使用情况进行回顾性调查研究。结果 川北医学院附属医院心内科2017年住院的慢性心力衰竭患者共486名,其主要病因为缺血性心脏病;其中309名使用β受体阻滞剂(63.58%);均使用第二代β受体阻滞剂,包括美托洛尔和比索洛尔,平均使用剂量分别为31.65 mg/d、3.33 mg/d;其中美托洛尔最常使用,共247名(79.94%)。使用β受体阻滞剂组和未使用β受体阻滞剂组在性别、年龄、NYHA心功能分级方面比较差异具有统计学意义(P<0.05),而射血分数、心率方面比较差异无统计学意义(P>0.05)。β受体阻滞剂能降低慢性心力衰竭患者的心率、收缩压及舒张压,差异均具有统计学意义(P<0.001),而患者出院时心率达标率仅为2.91%。 结论 川北医学院附属医院2017年慢性心力衰竭患者主要病因为缺血性心脏病;慢性心力衰竭患者均使用第二代β受体阻滞剂,其中美托洛尔最常使用;性别、年龄及NYHA心功能分级可能是影响川北医学院附属医院慢性心力衰竭患者使用β受体阻滞剂的因素;慢性心力衰竭患者使用β受体阻滞剂后心率、血压较使用前降低,但出院时心率达标率极低。
关键词:  慢性  心力衰竭  β受体阻滞剂  流行病学
DOI:
基金项目:四川省南充市校科技战略合作专项(NSMC20170210)
Use of β-blockers during hospitalization in patients with chronic heart failure
ZENG Jing,WANG Xiaobo,LU Shengzhong,LIANG Hao,QIN Dan,HU Houxiang
(Department of Cardiology, The Affiliated Hospital of North Sichuan Medical College)
Abstract:
【Abstract】 Objective To make a detailed survey of the status for βblockers using on chronic heart failure (CHF) during hospitalization in the Department of Cardiology, The Affiliated Hospital of North Sichuan Medical College. Methods A retrospective investigation was conducted on the use of βblockers in patients with chronic heart failure in 2017 by using the database of inpatients in the Affiliated Hospital of North Sichuan Medical College. Results 486 patients with CHF were hospitalized in 2017 in the Department of Cardiology, Affiliated Hospital of North Sichuan Medical College, mainly due to ischemic heart disease. Among them, 309 patients (63.58%) used β-blockers. They all used secondgeneration βblockers, including metoprolol and bisoprolol, with an average dose of 3165 mg/d and 333 mg/d. Metoprolol (247 cases, 79.94% ) was the most commonly used. There was a significant statistical difference in gender, age, and New York Heart Association (NYHA) functional class (P<0.05). There was no statistical difference between the two groups in terms of ejection fraction and heart rate (P>0.05). βblockers can reduce heart rate, systolic blood pressure and diastolic blood pressure in patients with CHF, there was a significant statistical difference between them(P<0.001). Its controlling rate of heart rate was only 2.91%. Conclusion In 2017, the main cause of chronic heart failure in the Affiliated Hospital of North Sichuan Medical College was ischemic heart disease. Second generation beta blockers were used in all patients with chronic heart failure, metoprolol was the most commonly used. Sex, age and NYHA classification may be the factors that affect the use of β - blockers in patients with chronic heart failure in the Affiliated Hospital of North Sichuan Medical College. The heart rate and blood pressure of patients with chronic heart failure after using β - blocker were lower than before, but the rate of heart rate reaching standard was very low at discharge.
Key words:  Heart failure  β-blockers  Epidemiology  Retrospective study

用微信扫一扫

用微信扫一扫